Estrés oxidativo en las complicaciones microvasculares de la diabetes mellitus tipo 2: mecanismos moleculares y perspectivas terapéuticas
Barra lateral del artículo
Publicado:
Aug 24, 2026
Palabras clave:
Estrés Oxidativo; Diabetes Mellitus Tipo 2; Especies Reactivas de Oxígeno; Retinopatía Diabética; Nefropatías Diabéticas; Neuropatías Diabéticas
Contenido principal del artículo
Resumen
La diabetes mellitus tipo 2 (DM2) constituye un problema creciente de salud pública por la frecuencia y gravedad de sus
complicaciones microvasculares. Esta revisión analiza el papel del estrés oxidativo (EO), sus fuentes celulares, las vías
metabólicas activadas por la hiperglucemia y su relación con la retinopatía diabética (RD), nefropatía diabética (ND) y
neuropatía diabética (NPD). La evidencia revisada indica que la sobreproducción de especies reactivas de oxígeno (ERO),
activación de las vías del poliol, hexosaminas y proteína cinasa C (PKC), así como la señalización mediada por productos finales
de glicación avanzada (AGEs), convergen en inflamación, disfunción endotelial, aumento de la permeabilidad vascular, hipoxia y
fibrosis. Asimismo, biomarcadores de daño oxidativo y estrategias dirigidas a fortalecer la defensa antioxidante muestran
utilidad potencial, aunque requieren validación clínica. En conclusión, el EO constituye un nexo fisiopatológico central y una
posible diana terapéutica para prevenir la progresión del daño microvascular en la DM2.
Detalles del artículo
Cómo citar
Teodoro Maza, J., Trujillo Villanueva, Z., Unyen Castañeda, X., Valverde Maya, Z., & Vasquez Flores, J. (2026). Estrés oxidativo en las complicaciones microvasculares de la diabetes mellitus tipo 2: mecanismos moleculares y perspectivas terapéuticas . Revista Médica Del Santa, 1(1), 32 - 42. https://doi.org/10.71173/rev.medica.santa.2026.v1n1.05
Número
Sección
Artículos
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0.
Citas
Yaribeygi H, Sathyapalan T, Atkin SL, Sahebkar A. Molecular mechanisms linking oxidative stress and diabetes mellitus. Oxid Med Cell Longev. 2020;2020:8609213. doi:10.1155/2020/8609213.
Zhang L, Yang M, Qin S, Han L, Cheng W. Hyperglycemia-induced mitochondrial dysfunction and oxidative stress in diabetes microvascular complications. Front Endocrinol (Lausanne). 2023;14:1164925. doi:10.3389/fendo.2023.1164925.
Kang Q, Yang C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020;37:101799. doi:10.1016/j.redox.2020.101799.
Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032-2045. doi:10.2215/CJN.11491116.
Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5(1):41. doi:10.1038/s41572-019-0092-1.
Guo X, Xing Y, Jin W. Role of ADMA in the pathogenesis of microvascular complications in type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2023 Apr 21;14:1183586. doi: 10.3389/fendo.2023.1183586. PMID: 37152974; PMCID: PMC10160678.
Ighodaro OM. Vías moleculares asociadas con el estrés oxidativo en la diabetes mellitus. Biomed Pharmacother. 2018;108:656-662. Disponible en: https://doi.org/10.1016/j.biopha.2018.09.058
Rabbani N, Thornalley PJ. Advanced glycation endproducts in the pathogenesis of chronic kidney disease. Kidney Int. 2018;93(4):803-813. Disponible en: https://doi.org/10.1016/j.kint.2017.11.034
Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Taylor & Francis Korean J Physiol Pharmacol. 2014;18(1):1-14. doi:10.4196/kjpp.2014.18.1.1.
Yan L-J. Redox imbalance stress in diabetes mellitus: Role of the polyol pathway. Animal Model Exp Med . 2018;1(1):7–13. http://dx.doi.org/10.1002/ame2.12001
Papachristoforou E, Lambadiari V, Maratou E, Makrilakis K. Association of Glycemic Indices (Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic Complications. J Diabetes Res. 2020;2020:7489795. doi: 10.1155/2020/7489795
Huang H, Luo Y, Wang Q, Zhang Y, Li Z, He R, Chen X, Dong Z. Vaccinium as Potential Therapy for Diabetes and Microvascular Complications. Nutrients. 2023;15(9):2031. doi: 10.3390/nu15092031.
Sheweita SA, Mashaly S, Newairy AA, Abdou HM, Eweda SM. Changes in Oxidative Stress and Antioxidant Enzyme Activities in Streptozotocin-Induced Diabetes Mellitus in Rats: role of Alhagi maurorum extracts. Oxid Med Cell Longev. 2016;2016:5264064. doi: 10.1155/2016/5264064.
Lee J, Yun JS, Ko SH. Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus. Nutrients. 2022;14(15):3086. doi: 10.3390/nu14153086.
Sun M, Yan G, Sun S, Li X, Sun W, Wang Y. Malondialdehyde and Zinc May Relate to Severity of Microvascular Complications in Diabetes: A Preliminary Study on Older Adults with Type 2 Diabetes Mellitus in Northeast China. Clin Interv Aging. 2024;19:1141-1151. doi: 10.2147/CIA.S464615.
Linkens AMA, Houben AJHM, Niessen PM, Wijckmans NEG, de Goei EEC, Van den Eynde MDG, et al. A 4-week high-AGE diet does not impair glucose metabolism and vascular function in obese individuals. JCI Insight. 2022;7(6):e156950. doi: 10.1172/jci.insight.156950.
Waris S, Winklhofer-Roob BM, Roob JM, Fuchs S, Sourij H, Rabbani N, et al. Increased DNA Dicarbonyl Glycation and Oxidation Markers in Patients with Type 2 Diabetes and Link to Diabetic Nephropathy. J Diabetes Res. 2015;2015:915486. doi: 10.1155/2015/915486.
Liu J, Li C, Chen W, He K, Ma H, Ma B, et al. Relationship between Serum Asymmetric Dimethylarginine Level and Microvascular Complications in Diabetes Mellitus: A Meta-Analysis. BioMed Res Int. 2019;2019:2941861. doi: 10.1155/2019/2941861.
Cortese MM, Suschek CV, Wetzel W, Kröncke KD, Kolb-Bachofen V. Zinc protects endothelial cells from hydrogen peroxide via Nrf2-dependent stimulation of glutathione biosynthesis. Free Radic Biol Med. 2008;44(12):2002-2012. doi: 10.1016/j.freeradbiomed.2008.02.013.
Alqasoumi SI, Al-Rehaily AJ, AlSheikh AM, Abdel-Kader MS. Evaluation of the Hepatoprotective effect of Ephedra foliate, Alhagi maurorum, Capsella bursa-pastoris and Hibiscus sabdariffa Against Experimentally Induced Liver Injury in Rats. Nat Prod Sci. 2008;14(2):95-99.
Giacco F, Brownlee M. Oxidative Stress and Diabetic Complications. Circ Res. 2010;107(9):1058-1070. doi: 10.1161/CIRCRESAHA.110.223545.
Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Nature. 2005;434(7035):813-820. doi:10.1038/nature03521.
Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137-188. doi:10.1152/physrev.00045.2011.
Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res. 2010;106(8):1319-1331. doi:10.1161/CIRCRESAHA.110.217117.
Böger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med. 2006;38(2):126-136. doi:10.1080/07853890600585711.
Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33(7):829-837. doi:10.1093/eurheartj/ehr304.
Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006;113(13):1708-1714. doi:10.1161/CIRCULATIONAHA.105.602532.
Daiber A, Xia N, Steven S, Oelze M, Hanf A, Kröller-Schön S, Münzel T. New therapeutic implications of endothelial nitric oxide synthase (eNOS) function/dysfunction in cardiovascular disease. Int J Mol Sci. 2019;20(1):187. doi:10.3390/ijms20010187.
Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19(3):433-442. doi:10.1681/ASN.2007091048.
Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98-107. doi:10.1038/nri2925.
Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009;94(9):3171-3182. doi:10.1210/jc.2008-2534.
Simó R, Hernández C. Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. Prog Retin Eye Res. 2015;48:160-180. doi:10.1016/j.preteyeres.2015.04.003.
Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet. 1998;352(9123):213-219. doi:10.1016/S0140-6736(98)01346-4.
Kanwar YS, Sun L, Xie P, Liu FY, Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol. 2011;6:395-423. doi:10.1146/annurev-pathol-011110-130250.
Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399-408. doi:10.1016/j.cell.2012.01.021.
Chiu CJ, Taylor A. Dietary hyperglycemia, glycemic index and metabolic retinal diseases. Prog Retin Eye Res. 2011;30(1):18-53. doi:10.1016/j.preteyeres.2010.11.001.
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124-136. doi:10.1016/S0140-6736(09)62124-3.
Wong TY, Cheung CMG, Larsen M, Sharma S, Simó R. Diabetic retinopathy. Nat Rev Dis Primers. 2016;2:16012. doi:10.1038/nrdp.2016.12.
Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227-1239. doi:10.1056/NEJMra1005073.
Hammes HP. Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond. Diabetologia. 2018;61(1):29-38. doi:10.1007/s00125-017-4435-8.
Klaassen I, Van Noorden CJF, Schlingemann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res. 2013;34:19-48. doi:10.1016/j.preteyeres.2013.02.001.
Semeraro F, Cancarini A, Dell'Omo R, Rezzola S, Romano MR, Costagliola C. Diabetic retinopathy: vascular and inflammatory disease. J Diabetes Res. 2015;2015:582060. doi:10.1155/2015/582060.
Simó R, Sundstrom JM, Antonetti DA. Ocular anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care. 2014;37(4):893-899. doi:10.2337/dc13-2002.
Stitt AW, Curtis TM, Chen M, Medina RJ, McKay GJ, Jenkins A, Gardiner TA, Lyons TJ, Hammes HP, Simó R, Lois N. The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res. 2016;51:156-186. doi:10.1016/j.preteyeres.2015.08.001.
Wilkinson CP, Ferris FL III, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677-1682. doi:10.1016/S0161-6420(03)00475-5.
Pan D, Xu L, Guo M. The role of protein kinase C in diabetic microvascular complications. Front Endocrinol (Lausanne). 2022;13:973058. doi:10.3389/fendo.2022.973058.
Vallon V, Thomson SC. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol. 2020;16(6):317-336. doi:10.1038/s41581-020-0256-y.
Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KAM, Zoungas S, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018. doi:10.1038/nrdp.2015.18.
Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Invest. 2014;124(6):2333-2340.
Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136-154. doi:10.2337/dc16-2042.
Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011;7(10):573-583. doi:10.1038/nrneurol.2011.137
Zhang L, Yang M, Qin S, Han L, Cheng W. Hyperglycemia-induced mitochondrial dysfunction and oxidative stress in diabetes microvascular complications. Front Endocrinol (Lausanne). 2023;14:1164925. doi:10.3389/fendo.2023.1164925.
Kang Q, Yang C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020;37:101799. doi:10.1016/j.redox.2020.101799.
Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032-2045. doi:10.2215/CJN.11491116.
Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5(1):41. doi:10.1038/s41572-019-0092-1.
Guo X, Xing Y, Jin W. Role of ADMA in the pathogenesis of microvascular complications in type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2023 Apr 21;14:1183586. doi: 10.3389/fendo.2023.1183586. PMID: 37152974; PMCID: PMC10160678.
Ighodaro OM. Vías moleculares asociadas con el estrés oxidativo en la diabetes mellitus. Biomed Pharmacother. 2018;108:656-662. Disponible en: https://doi.org/10.1016/j.biopha.2018.09.058
Rabbani N, Thornalley PJ. Advanced glycation endproducts in the pathogenesis of chronic kidney disease. Kidney Int. 2018;93(4):803-813. Disponible en: https://doi.org/10.1016/j.kint.2017.11.034
Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Taylor & Francis Korean J Physiol Pharmacol. 2014;18(1):1-14. doi:10.4196/kjpp.2014.18.1.1.
Yan L-J. Redox imbalance stress in diabetes mellitus: Role of the polyol pathway. Animal Model Exp Med . 2018;1(1):7–13. http://dx.doi.org/10.1002/ame2.12001
Papachristoforou E, Lambadiari V, Maratou E, Makrilakis K. Association of Glycemic Indices (Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic Complications. J Diabetes Res. 2020;2020:7489795. doi: 10.1155/2020/7489795
Huang H, Luo Y, Wang Q, Zhang Y, Li Z, He R, Chen X, Dong Z. Vaccinium as Potential Therapy for Diabetes and Microvascular Complications. Nutrients. 2023;15(9):2031. doi: 10.3390/nu15092031.
Sheweita SA, Mashaly S, Newairy AA, Abdou HM, Eweda SM. Changes in Oxidative Stress and Antioxidant Enzyme Activities in Streptozotocin-Induced Diabetes Mellitus in Rats: role of Alhagi maurorum extracts. Oxid Med Cell Longev. 2016;2016:5264064. doi: 10.1155/2016/5264064.
Lee J, Yun JS, Ko SH. Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus. Nutrients. 2022;14(15):3086. doi: 10.3390/nu14153086.
Sun M, Yan G, Sun S, Li X, Sun W, Wang Y. Malondialdehyde and Zinc May Relate to Severity of Microvascular Complications in Diabetes: A Preliminary Study on Older Adults with Type 2 Diabetes Mellitus in Northeast China. Clin Interv Aging. 2024;19:1141-1151. doi: 10.2147/CIA.S464615.
Linkens AMA, Houben AJHM, Niessen PM, Wijckmans NEG, de Goei EEC, Van den Eynde MDG, et al. A 4-week high-AGE diet does not impair glucose metabolism and vascular function in obese individuals. JCI Insight. 2022;7(6):e156950. doi: 10.1172/jci.insight.156950.
Waris S, Winklhofer-Roob BM, Roob JM, Fuchs S, Sourij H, Rabbani N, et al. Increased DNA Dicarbonyl Glycation and Oxidation Markers in Patients with Type 2 Diabetes and Link to Diabetic Nephropathy. J Diabetes Res. 2015;2015:915486. doi: 10.1155/2015/915486.
Liu J, Li C, Chen W, He K, Ma H, Ma B, et al. Relationship between Serum Asymmetric Dimethylarginine Level and Microvascular Complications in Diabetes Mellitus: A Meta-Analysis. BioMed Res Int. 2019;2019:2941861. doi: 10.1155/2019/2941861.
Cortese MM, Suschek CV, Wetzel W, Kröncke KD, Kolb-Bachofen V. Zinc protects endothelial cells from hydrogen peroxide via Nrf2-dependent stimulation of glutathione biosynthesis. Free Radic Biol Med. 2008;44(12):2002-2012. doi: 10.1016/j.freeradbiomed.2008.02.013.
Alqasoumi SI, Al-Rehaily AJ, AlSheikh AM, Abdel-Kader MS. Evaluation of the Hepatoprotective effect of Ephedra foliate, Alhagi maurorum, Capsella bursa-pastoris and Hibiscus sabdariffa Against Experimentally Induced Liver Injury in Rats. Nat Prod Sci. 2008;14(2):95-99.
Giacco F, Brownlee M. Oxidative Stress and Diabetic Complications. Circ Res. 2010;107(9):1058-1070. doi: 10.1161/CIRCRESAHA.110.223545.
Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Nature. 2005;434(7035):813-820. doi:10.1038/nature03521.
Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137-188. doi:10.1152/physrev.00045.2011.
Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res. 2010;106(8):1319-1331. doi:10.1161/CIRCRESAHA.110.217117.
Böger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med. 2006;38(2):126-136. doi:10.1080/07853890600585711.
Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33(7):829-837. doi:10.1093/eurheartj/ehr304.
Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006;113(13):1708-1714. doi:10.1161/CIRCULATIONAHA.105.602532.
Daiber A, Xia N, Steven S, Oelze M, Hanf A, Kröller-Schön S, Münzel T. New therapeutic implications of endothelial nitric oxide synthase (eNOS) function/dysfunction in cardiovascular disease. Int J Mol Sci. 2019;20(1):187. doi:10.3390/ijms20010187.
Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19(3):433-442. doi:10.1681/ASN.2007091048.
Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98-107. doi:10.1038/nri2925.
Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009;94(9):3171-3182. doi:10.1210/jc.2008-2534.
Simó R, Hernández C. Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. Prog Retin Eye Res. 2015;48:160-180. doi:10.1016/j.preteyeres.2015.04.003.
Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet. 1998;352(9123):213-219. doi:10.1016/S0140-6736(98)01346-4.
Kanwar YS, Sun L, Xie P, Liu FY, Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol. 2011;6:395-423. doi:10.1146/annurev-pathol-011110-130250.
Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399-408. doi:10.1016/j.cell.2012.01.021.
Chiu CJ, Taylor A. Dietary hyperglycemia, glycemic index and metabolic retinal diseases. Prog Retin Eye Res. 2011;30(1):18-53. doi:10.1016/j.preteyeres.2010.11.001.
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124-136. doi:10.1016/S0140-6736(09)62124-3.
Wong TY, Cheung CMG, Larsen M, Sharma S, Simó R. Diabetic retinopathy. Nat Rev Dis Primers. 2016;2:16012. doi:10.1038/nrdp.2016.12.
Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227-1239. doi:10.1056/NEJMra1005073.
Hammes HP. Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond. Diabetologia. 2018;61(1):29-38. doi:10.1007/s00125-017-4435-8.
Klaassen I, Van Noorden CJF, Schlingemann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res. 2013;34:19-48. doi:10.1016/j.preteyeres.2013.02.001.
Semeraro F, Cancarini A, Dell'Omo R, Rezzola S, Romano MR, Costagliola C. Diabetic retinopathy: vascular and inflammatory disease. J Diabetes Res. 2015;2015:582060. doi:10.1155/2015/582060.
Simó R, Sundstrom JM, Antonetti DA. Ocular anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care. 2014;37(4):893-899. doi:10.2337/dc13-2002.
Stitt AW, Curtis TM, Chen M, Medina RJ, McKay GJ, Jenkins A, Gardiner TA, Lyons TJ, Hammes HP, Simó R, Lois N. The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res. 2016;51:156-186. doi:10.1016/j.preteyeres.2015.08.001.
Wilkinson CP, Ferris FL III, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677-1682. doi:10.1016/S0161-6420(03)00475-5.
Pan D, Xu L, Guo M. The role of protein kinase C in diabetic microvascular complications. Front Endocrinol (Lausanne). 2022;13:973058. doi:10.3389/fendo.2022.973058.
Vallon V, Thomson SC. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol. 2020;16(6):317-336. doi:10.1038/s41581-020-0256-y.
Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KAM, Zoungas S, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018. doi:10.1038/nrdp.2015.18.
Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Invest. 2014;124(6):2333-2340.
Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136-154. doi:10.2337/dc16-2042.
Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011;7(10):573-583. doi:10.1038/nrneurol.2011.137